MCM
PGNX

Matarin Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Matarin Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-25,228
Closed -$238K – 311
2017
Q1 		$238K Buy
+25,228
New +$252K 0.02% 262

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Matarin Capital Management's PGNX Position: Q2 2017 in Review

Matarin Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2017, closing a stake of 25,228 shares — an estimated $238K sold.

Matarin Capital Management first reported a position in PGNX in Q1 2017 and held it in 1 quarter. The position peaked at $238K in Q1 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • Matarin Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Matarin Capital Management sold 25,228 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $238K.
  • Matarin Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 1 quarter.
  • Matarin Capital Management's Progenics Pharmaceuticals Inc position peaked at $238K in Q1 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on Matarin Capital Management's 13F filing for Q2 2017, filed 9 Aug 2017.